Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - InspirePharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.Shaffer, Ph.D., President and CEO, will present at the C.E.Unterberg, Towbin Emerging Growth Opportunities Conference onWednesday, July 11, 2007 at 11:00 am ET in New York City. The
webcast of the presentation will be available on Inspire'sweb site at www.inspirepharm.com...
Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin
Emerging Growth Opportunities Conference
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 03, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today that J. Michael French, Rosetta GenomicsPresident, will present at CE Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, at 11:00 am EST atthe Mandarin Oriental Hotel in New York. A live audio
webcast o...
GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.
Unterberg, Towbin Emerging Growth Life Opportunities Conference
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...
Iomai to Announce Results From Phase 1 Influenza Trial and Host
Webcast Tomorrow
GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -- IomaiCorporation today announced that it will announce results from thePhase 1 trial of its patch-based needle-free influenza vaccinebefore the markets open tomorrow. A conference call and live
webcast will be held at 8:30 a.m. Eastern Time tomorrow to discussthe results. To access the live conf...
Isis Pharmaceuticals Announces Its Participation at the Upcoming
ACC 56th Annual Scientific Session in New Orleans and Its Live
Analyst/Investor Webcast Presentation
CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals announces that results from three Phase 2 studiesof ISIS 301012, including effects of ISIS 301012 in homozygousfamilial hypercholesterolemic (HoFH) patients, will be the subjectsof three upcoming presentations at the of Cardiology (ACC), March24-27 in New Orleans. Planned presentations include effects of ISIS3...